Omeros has received approval from the US Food and Drug Administration (FDA) for its Omidria for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain.

Claimed to be the first commercial product from the company’s PharmacoSurgery platform, Omidria is a combination of the pupil-dilating agent phenylephrine (1%) and the anti-inflammatory agent ketorolac (0.3%).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to Omeros, FDA approval comes with no post-marketing commitments other than the previously agreed study of Omidria for use in paediatric patients, which, if successfully completed, makes the drug eligible for an additional six months of marketing exclusivity in the US.

"In pivotal clinical trials, Omidria showed statistically significant and clinically meaningful improvement in preventing miosis and reduction of postoperative pain relative to placebo."

In pivotal clinical trials, Omidria showed statistically significant and clinically meaningful improvement in preventing miosis and reduction of postoperative pain relative to placebo.

Patients in these clinical trials received standard pupil-dilating and anesthetic agents prior to surgery.

Ocular adverse reactions observed in the trials included eye irritation, posterior capsule opacification, increased intraocular pressure and anterior chamber inflammation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Omeros is expected to launch Omidria in the US around September.

Omeros chairman and CEO Gregory Demopulos said: "We have continued to round out our commercialisation team and are focused on obtaining European approval for Omidria, securing Medicare pass-through reimbursement and successfully launching the product in the US later this year.

"In parallel, our premier clinical and non-clinical programmes are advancing, and we look forward to sales of Omidria significantly defraying future development costs of our rich pipeline."

Currently, the European Medicines Agency is reviewing the marketing authorisation application for Omidria.